ARTICLE | Management Tracks
Jin promoted to CEO at Ensem
Plus: Pedranti named CEO at Visgenx, and updates from Altoida, Vaxxas, Variant, Immodulon and Google Ventures
June 6, 2023 12:10 AM UTC
CBC portfolio company Ensem Therapeutics Inc. promoted co-founder, President and CSO Shengfang Jin to president and CEO. Ensem is developing cancer therapies using its Kinetic Ensemble platform, focusing on difficult-to-drug targets, and plans to takes its first program into the clinic next year.
Gene therapy company Visgenx Inc. named William Pedranti as CEO and board member. Pedranti was a partner with PENG Life Science Ventures, which he co-founded. Visgenx’ lead program, VGX-0111, is designed to restore ELOVL2 expression to treat dry age-related macular degeneration. ...